Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT00500292
First received: July 3, 2007
Last updated: February 20, 2017
Last verified: February 2017
  Purpose
The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.

Condition Intervention Phase
Colorectal
Cancer
Drug: Vandetanib
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen

Resource links provided by NLM:


Further study details as provided by Sanofi ( Genzyme, a Sanofi Company ):

Primary Outcome Measures:
  • Number of Patients With an Objective Disease Progression Event [ Time Frame: RECIST tumour assessments carried out at screening and then as per site clinical practice until objective progression. The only additional mandatory tumour assessment visit is at the point of data cut-off (5 March 2008 +/-3 days) ]
    Number of patients with objective disease progression or death (by any cause in the absence of objective progression)


Enrollment: 109
Study Start Date: March 2007
Study Completion Date: November 2016
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
FOLFOX + Placebo vandetanib
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
intravenous infusion
Experimental: 2
FOLFOX + low dose vandetanib
Drug: Vandetanib
once daily oral tablet two dose strengths
Other Names:
  • AZ6474
  • ZACTIMA™
  • SAR390530
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
intravenous infusion
Experimental: 3
FOLFOX + high dose vandetanib
Drug: Vandetanib
once daily oral tablet two dose strengths
Other Names:
  • AZ6474
  • ZACTIMA™
  • SAR390530
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
intravenous infusion

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Progression on or following treatment for metastatic colorectal cancer
  • Have failed therapy with an irinotecan and fluoropyrimidine containing regimen
  • Have World Health Organisation (WHO) performance status 0-2 and life expectancy >12 weeks

Exclusion Criteria:

  • Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR Prior monoclonal antibodies are permitted, (eg, cetuximab, bevacizumab)
  • Previous adjuvant therapy with irinotecan within 12 months of randomisation
  • More than one prior course of chemotherapy for treatment of metastatic colorectal cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00500292

Locations
France
Research Site
Lille Cedex, France
Research Site
Toulouse Cedex 9, France
Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Szeged, Hungary
Korea, Republic of
Research Site
Seoul, Korea, Republic of
Slovakia
Research Site
Bratislava, Slovakia
Research Site
Poprad, Slovakia
Research Site
Trnava, Slovakia
Research Site
Zilina, Slovakia
Spain
Research Site
Hospitalet deLlobregat, Spain
Research Site
Oviedo, Spain
Research Site
Santander, Spain
Taiwan
Research Site
Taipei, Taiwan
Research Site
Tao-Yuan, Taiwan
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Additional Information:
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT00500292     History of Changes
Other Study ID Numbers: D4200C00047
2006-005022-23 ( EudraCT Number )
LPS15025 ( Other Identifier: Sanofi )
Study First Received: July 3, 2007
Results First Received: April 27, 2011
Last Updated: February 20, 2017

Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
colorectal
cancer
zactima

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Fluorouracil
Oxaliplatin
Leucovorin
Levoleucovorin
Folic Acid
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antidotes
Protective Agents
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Hematinics

ClinicalTrials.gov processed this record on May 25, 2017